Pembrolizumab as the first-line monotherapy for non-small-cell lung cancer with a low programmed death ligand 1 threshold

Journal of Cell Communication and Signaling

article

Xu, Zhijie¹  Wang, Xiang³  Chen, Xi³  Zeng, Shuangshuang³  Gong, Zhicheng³  Yan, Yuanliang³ 

[1] Department of Pathology, Xiangya Hospital, Central South University;National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University;Department of Pharmacy, Xiangya Hospital, Central South University

关键词: Pembrolizumab;    NSCLC;    PD-L1;    TPS;    Hyperprogressive disease;   

DOI  :  10.1007/s12079-020-00547-6

学科分类：分子生物学，细胞生物学和基因

来源: Springer

【 摘 要 】

Pembrolizumab monotherapy has been demonstrated as a first-line therapy for non-small-cell lung cancer (NSCLC) patients with a programmed death ligand 1 (PD-L1) tumor proportion score (TPS) of ≥50%; however, the clinical efficacy is limited by the unreasonable threshold of the TPS. A recent study published by Mok et al. (Lancet 393:1819–1830, 2019) showed that pembrolizumab monotherapy could also be extended as an effective first-line therapeutic strategy for NSCLC patients with low TPS. However, this needs to be further evaluated in detail after considering the following issues. In Mok’s report, the survival curves were much lower in a pembrolizumab-treated group in the first 6 months of treatment compared with a chemotherapy group. These contradictory findings might have been due to anecdotal occurrences of rapid progression, especially hyperprogressive disease.

【 授权许可】

CC BY